JP2019520797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520797A5 JP2019520797A5 JP2018557864A JP2018557864A JP2019520797A5 JP 2019520797 A5 JP2019520797 A5 JP 2019520797A5 JP 2018557864 A JP2018557864 A JP 2018557864A JP 2018557864 A JP2018557864 A JP 2018557864A JP 2019520797 A5 JP2019520797 A5 JP 2019520797A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- binding protein
- amino acid
- bispecific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 108091008324 binding proteins Proteins 0.000 claims description 22
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 102000023732 binding proteins Human genes 0.000 description 13
- 239000002904 solvent Substances 0.000 description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158292A JP7171867B2 (ja) | 2016-05-06 | 2021-09-28 | 二重特異性結合タンパク質およびその使用 |
| JP2022177063A JP2023012528A (ja) | 2016-05-06 | 2022-11-04 | 二重特異性結合タンパク質およびその使用 |
| JP2024005009A JP7651022B2 (ja) | 2016-05-06 | 2024-01-17 | 二重特異性結合タンパク質およびその使用 |
| JP2025039002A JP2025090743A (ja) | 2016-05-06 | 2025-03-12 | 二重特異性結合タンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332788P | 2016-05-06 | 2016-05-06 | |
| US62/332,788 | 2016-05-06 | ||
| PCT/US2017/031356 WO2017193032A2 (en) | 2016-05-06 | 2017-05-05 | Bispecific binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158292A Division JP7171867B2 (ja) | 2016-05-06 | 2021-09-28 | 二重特異性結合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520797A JP2019520797A (ja) | 2019-07-25 |
| JP2019520797A5 true JP2019520797A5 (https=) | 2020-06-18 |
| JP6952716B2 JP6952716B2 (ja) | 2021-10-20 |
Family
ID=60203374
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557864A Active JP6952716B2 (ja) | 2016-05-06 | 2017-05-05 | 二重特異性結合タンパク質およびその使用 |
| JP2021158292A Active JP7171867B2 (ja) | 2016-05-06 | 2021-09-28 | 二重特異性結合タンパク質およびその使用 |
| JP2022177063A Pending JP2023012528A (ja) | 2016-05-06 | 2022-11-04 | 二重特異性結合タンパク質およびその使用 |
| JP2024005009A Active JP7651022B2 (ja) | 2016-05-06 | 2024-01-17 | 二重特異性結合タンパク質およびその使用 |
| JP2025039002A Pending JP2025090743A (ja) | 2016-05-06 | 2025-03-12 | 二重特異性結合タンパク質およびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158292A Active JP7171867B2 (ja) | 2016-05-06 | 2021-09-28 | 二重特異性結合タンパク質およびその使用 |
| JP2022177063A Pending JP2023012528A (ja) | 2016-05-06 | 2022-11-04 | 二重特異性結合タンパク質およびその使用 |
| JP2024005009A Active JP7651022B2 (ja) | 2016-05-06 | 2024-01-17 | 二重特異性結合タンパク質およびその使用 |
| JP2025039002A Pending JP2025090743A (ja) | 2016-05-06 | 2025-03-12 | 二重特異性結合タンパク質およびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10457732B2 (https=) |
| EP (2) | EP4736954A2 (https=) |
| JP (5) | JP6952716B2 (https=) |
| KR (3) | KR102674279B1 (https=) |
| CN (1) | CN109152835B (https=) |
| AR (1) | AR108377A1 (https=) |
| AU (3) | AU2017260365B2 (https=) |
| CL (1) | CL2018003136A1 (https=) |
| CO (1) | CO2018012415A2 (https=) |
| DK (1) | DK3452089T3 (https=) |
| FI (1) | FI3452089T3 (https=) |
| IL (3) | IL321475A (https=) |
| LT (1) | LT3452089T (https=) |
| MA (1) | MA44885B1 (https=) |
| MX (2) | MX2018013548A (https=) |
| MY (1) | MY200335A (https=) |
| NZ (3) | NZ787944A (https=) |
| PT (1) | PT3452089T (https=) |
| RU (2) | RU2766199C2 (https=) |
| SG (1) | SG11201809089QA (https=) |
| TW (3) | TWI831124B (https=) |
| WO (1) | WO2017193032A2 (https=) |
| ZA (1) | ZA201808160B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| ES2981272T3 (es) | 2016-09-23 | 2024-10-08 | Merus Nv | Moléculas de unión que modulan una actividad biológica expresada por una célula |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| WO2018193063A2 (en) | 2017-04-19 | 2018-10-25 | Institute For Research In Biomedicine | Novel malaria vaccines and antibodies binding to plasmodium sporozoites |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP3728316B1 (en) * | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| EP3732203A4 (en) | 2017-12-28 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1 |
| AU2018394939B2 (en) * | 2017-12-29 | 2022-02-24 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| US11046769B2 (en) * | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| JP2022525275A (ja) * | 2019-03-28 | 2022-05-12 | エービー ストゥーディオ インコーポレイテッド | ヘテロ多量体タンパク質及びその使用法 |
| US11718673B2 (en) | 2019-04-01 | 2023-08-08 | Immetas Therapeutics, Inc. | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein |
| CN110229232B (zh) * | 2019-06-19 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 双特异性抗体及其用途 |
| JP2022553176A (ja) * | 2019-10-17 | 2022-12-22 | 江蘇康寧杰瑞生物制薬有限公司 | Ｏｘ４０／ｐｄ－ｌ１二重特異性抗体 |
| US20230340119A1 (en) * | 2019-12-05 | 2023-10-26 | Arbele Corp | Composition of triax antibodies and method of making and using thereof |
| WO2021185337A1 (zh) * | 2020-03-20 | 2021-09-23 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| JP7014250B2 (ja) | 2020-03-27 | 2022-02-01 | フジテック株式会社 | エレベータのドア装置用の動作設定装置、及び該動作設定装置を用いたドア装置の開閉動作の設定方法。 |
| TW202220691A (zh) * | 2020-07-27 | 2022-06-01 | 美商宏觀基因股份有限公司 | 用於使用ＰＤ—１ｘＣＴＬＡ—４雙特異性分子的方法 |
| CA3198102A1 (en) | 2020-10-07 | 2022-04-14 | Dren Bio, Inc. | Anti-dectin-1 antibodies and methods of use thereof |
| CN114573704B (zh) * | 2021-03-10 | 2022-11-01 | 北京拓界生物医药科技有限公司 | Pd-1/ctla-4结合蛋白及其医药用途 |
| CN117120091A (zh) * | 2021-04-13 | 2023-11-24 | 免疫医疗有限责任公司 | 靶向pd-1和tim-3的双特异性抗体 |
| MX2023012324A (es) * | 2021-04-20 | 2023-10-30 | Amgen Inc | Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. |
| EP4326773A4 (en) | 2021-04-23 | 2025-09-24 | Suzhou Neologics Bioscience Co Ltd | ANTIBODIES TARGETING TIM-3 AND THEIR USES |
| JP2024517558A (ja) | 2021-04-30 | 2024-04-23 | メディミューン，エルエルシー | 二重特異性ｐｄ－１及びｔｉｇｉｔ結合タンパク質並びにその使用 |
| CA3253514A1 (en) * | 2022-03-07 | 2023-09-14 | Medimmune Llc | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES |
| IL318624A (en) * | 2022-07-28 | 2025-03-01 | Medimmune Llc | Combination therapies for cancer treatment |
| TW202412859A (zh) | 2022-07-28 | 2024-04-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及雙特異性檢查點抑制劑之組合 |
| WO2024182781A1 (en) | 2023-03-02 | 2024-09-06 | Vir Biotechnology, Inc. | Coronavirus compositions and uses thereof |
| KR20250173543A (ko) * | 2023-04-13 | 2025-12-10 | 메디뮨 엘엘씨 | 암 치료를 위한 pd-1/tigit 결합 단백질 |
| KR20260013474A (ko) | 2023-05-17 | 2026-01-28 | 아스트라제네카 아베 | 자궁경부암을 치료하기 위한 방법 및 조합 |
| WO2024241246A1 (en) * | 2023-05-23 | 2024-11-28 | Medimmune, Llc | PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC AND cHL |
| WO2025088496A1 (en) | 2023-10-24 | 2025-05-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US20050226867A1 (en) | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1896071E (pt) | 2005-06-30 | 2015-07-09 | Janssen Biotech Inc | Métodos e composições com melhorias na atividade terapêutica |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| BRPI0907046A2 (pt) | 2008-01-18 | 2015-07-28 | Medimmune Llc | Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| CA2785907A1 (en) * | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| WO2011130324A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| EP2832671B1 (en) * | 2013-07-30 | 2016-07-13 | Hewlett-Packard Industrial Printing Ltd. | Printing apparatus and methods |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| CN103721255A (zh) * | 2014-01-07 | 2014-04-16 | 苏州大学 | 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途 |
| CA2936244A1 (en) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| PE20170255A1 (es) * | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) * | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| EP3149043A1 (en) | 2014-05-29 | 2017-04-05 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| KR102486180B1 (ko) * | 2014-06-06 | 2023-01-11 | 레드우드 바이오사이언스 인코포레이티드 | 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
-
2017
- 2017-05-04 AR ARP170101161A patent/AR108377A1/es unknown
- 2017-05-04 IL IL321475A patent/IL321475A/en unknown
- 2017-05-05 NZ NZ787944A patent/NZ787944A/en unknown
- 2017-05-05 EP EP25215412.5A patent/EP4736954A2/en active Pending
- 2017-05-05 RU RU2018142544A patent/RU2766199C2/ru active
- 2017-05-05 CN CN201780027207.XA patent/CN109152835B/zh active Active
- 2017-05-05 MX MX2018013548A patent/MX2018013548A/es unknown
- 2017-05-05 NZ NZ787945A patent/NZ787945A/en unknown
- 2017-05-05 PT PT177934809T patent/PT3452089T/pt unknown
- 2017-05-05 IL IL262437A patent/IL262437B2/en unknown
- 2017-05-05 TW TW111104211A patent/TWI831124B/zh active
- 2017-05-05 IL IL298286A patent/IL298286B2/en unknown
- 2017-05-05 NZ NZ748976A patent/NZ748976A/en unknown
- 2017-05-05 MY MYPI2018704132A patent/MY200335A/en unknown
- 2017-05-05 MA MA44885A patent/MA44885B1/fr unknown
- 2017-05-05 KR KR1020237001553A patent/KR102674279B1/ko active Active
- 2017-05-05 DK DK17793480.9T patent/DK3452089T3/da active
- 2017-05-05 LT LTEPPCT/US2017/031356T patent/LT3452089T/lt unknown
- 2017-05-05 RU RU2022102446A patent/RU2022102446A/ru unknown
- 2017-05-05 KR KR1020187034042A patent/KR102490183B1/ko active Active
- 2017-05-05 SG SG11201809089QA patent/SG11201809089QA/en unknown
- 2017-05-05 TW TW106115065A patent/TWI757290B/zh active
- 2017-05-05 FI FIEP17793480.9T patent/FI3452089T3/fi active
- 2017-05-05 TW TW113101203A patent/TWI890267B/zh active
- 2017-05-05 AU AU2017260365A patent/AU2017260365B2/en active Active
- 2017-05-05 WO PCT/US2017/031356 patent/WO2017193032A2/en not_active Ceased
- 2017-05-05 US US15/588,271 patent/US10457732B2/en not_active Ceased
- 2017-05-05 EP EP17793480.9A patent/EP3452089B1/en active Active
- 2017-05-05 KR KR1020247018987A patent/KR20240096787A/ko active Pending
- 2017-05-05 JP JP2018557864A patent/JP6952716B2/ja active Active
-
2018
- 2018-11-05 CL CL2018003136A patent/CL2018003136A1/es unknown
- 2018-11-06 MX MX2022015901A patent/MX2022015901A/es unknown
- 2018-11-19 CO CONC2018/0012415A patent/CO2018012415A2/es unknown
- 2018-12-03 ZA ZA2018/08160A patent/ZA201808160B/en unknown
-
2019
- 2019-09-13 US US16/570,966 patent/US11279759B2/en active Active
-
2020
- 2020-07-06 AU AU2020204497A patent/AU2020204497B2/en active Active
-
2021
- 2021-06-30 US US17/364,539 patent/USRE49908E1/en active Active
- 2021-09-28 JP JP2021158292A patent/JP7171867B2/ja active Active
- 2021-12-14 US US17/550,219 patent/US20220251204A1/en not_active Abandoned
-
2022
- 2022-11-04 JP JP2022177063A patent/JP2023012528A/ja active Pending
-
2023
- 2023-07-27 AU AU2023208166A patent/AU2023208166B2/en active Active
-
2024
- 2024-01-17 JP JP2024005009A patent/JP7651022B2/ja active Active
- 2024-09-11 US US18/882,194 patent/US20250074986A1/en active Pending
-
2025
- 2025-03-12 JP JP2025039002A patent/JP2025090743A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520797A5 (https=) | ||
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| US10781256B2 (en) | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | |
| JP2020525032A5 (https=) | ||
| JP2020063262A5 (https=) | ||
| JP2019116474A5 (https=) | ||
| JP2017520575A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2013515508A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| JP2018503380A5 (https=) | ||
| JP2018517431A5 (https=) | ||
| JP2013545738A5 (https=) | ||
| JP2013545455A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| US20230114801A1 (en) | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | |
| JP2020524661A5 (https=) | ||
| JP2022504826A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| JP2023532807A5 (https=) | ||
| JP2020502233A5 (https=) |